

HR 4392

To provide for the importation of pharmaceutical products under a compulsory license as provided for under the World Trade Organization.

Congress: 109 (2005–2007, Ended)

Chamber: House

Policy Area: Foreign Trade and International Finance

Introduced: Nov 18, 2005

Current Status: Referred to the House Committee on Ways and Means.

Latest Action: Referred to the House Committee on Ways and Means. (Nov 18, 2005)

Official Text: <https://www.congress.gov/bill/109th-congress/house-bill/4392>

Sponsor

Name: Rep. Allen, Thomas H. [D-ME-1]

Party: Democratic • **State:** ME • **Chamber:** House

Cosponsors (11 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Brown, Sherrod [D-OH-13]	D · OH		Dec 8, 2005
Rep. Grijalva, Raúl M. [D-AZ-7]	D · AZ		Dec 8, 2005
Rep. Sanders, Bernard [I-VT-At Large]	I · VT		Dec 8, 2005
Rep. Conyers, John, Jr. [D-MI-14]	D · MI		Dec 13, 2005
Rep. Stark, Fortney Pete [D-CA-13]	D · CA		Dec 13, 2005
Rep. Emanuel, Rahm [D-IL-5]	D · IL		Dec 16, 2005
Rep. Kucinich, Dennis J. [D-OH-10]	D · OH		Dec 16, 2005
Rep. Evans, Lane [D-IL-17]	D · IL		Jan 31, 2006
Rep. Case, Ed [D-HI-2]	D · HI		Apr 6, 2006
Rep. DeFazio, Peter A. [D-OR-4]	D · OR		Apr 6, 2006
Rep. Nadler, Jerrold [D-NY-8]	D · NY		May 3, 2006

Committee Activity

Committee	Chamber	Activity	Date
Ways and Means Committee	House	Referred To	Nov 18, 2005

Subjects & Policy Tags

Policy Area:

Foreign Trade and International Finance

Related Bills

No related bills are listed.

Requires the U.S. Trade Representative to inform the General Council of the World Trade Organization (WTO) that the United States: (1) declares itself an eligible importing member for the purpose of being able to import pharmaceutical products pursuant to the Decision of the General Council of August 30, 2003, on "Implementation of paragraph six of the Doha Declaration on the TRIPS Agreement and public health;" and (2) withdraws its name from the list contained in the "General Council Chairperson's Statement" accompanying such Decision, of countries that voluntarily relinquished the right to import pharmaceutical products manufactured under compulsory licenses.

Authorizes the President to import pharmaceutical products manufactured under a compulsory license to meet public health needs or to address situations of inadequate supply caused by insufficient domestic manufacturing capacity, in accordance with the Decision. Subjects such imported pharmaceutical products to the Federal Food, Drug, and Cosmetic Act.

Actions Timeline

- **Nov 18, 2005:** Introduced in House
- **Nov 18, 2005:** Introduced in House
- **Nov 18, 2005:** Sponsor introductory remarks on measure. (CR E2424-2425)
- **Nov 18, 2005:** Referred to the House Committee on Ways and Means.